Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

RVMD - Revolution Medicines, Inc.

IEX Last Trade
44.39
0.300   0.676%

Share volume: 0
Last Updated: Tue 24 Dec 2024 06:18:35 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 35.29%

PREVIOUS CLOSE
CHG
CHG%
$44.09
0.30
0.68%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 0%
Dept financing 4%
Liquidity 75%
Performance 4%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.75%
1 Month
-22.80%
3 Months
-1.05%
6 Months
14.32%
1 Year
62.66%
2 Year
101.41%
Key data
Stock price
$44.39
P/E Ratio 
-13.71
DAY RANGE
$44.09 - $44.17
EPS 
-$3.58
52 WEEK RANGE
$27.17 - $62.40
52 WEEK CHANGE
$51.45
MARKET CAP 
7.121 B
YIELD 
N/A
SHARES OUTSTANDING 
167.039 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
BETA 
1.52
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,381,757
AVERAGE 30 VOLUME 
$2,054,913
Company detail
CEO: Mark A. Goldsmith
Region: US
Website: revmed.com
Employees: 250
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Revolution Medicines, Inc. focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trials for solid tumors, such as gynecologic and colorectal cancer tumors.

Recent news